EU leaders have come under criticism for a slower rollout of vaccinations than in other countries such as Britain or the United States due to a longer approval and purchasing process and repeated delivery delays. AstraZeneca's new lower supply target hinges on the bloc's drug regulator approving supplies from a factory in the Netherlands, an internal document showed, Reuters reported on Saturday. Breton said that AstraZeneca had issues with testing, which were a sign of logistics problems, and urged its board of directors to take action.